<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20210825105100Z</creation_date><modification_date>D:20220829123200Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-20-1492_h_dec_3.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 2.9.2022c(2022) 6479 (final)</p></section><section><header>commission implementing decisionof 2.9.2022
 amending the conditional marketing authorisation granted by decision c(2020) 
 9284(final) for “tecartus - brexucabtagene autoleucel”, an orphan medicinal product 
 for human use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 2.9.2022
 amending the conditional marketing authorisation granted by decision c(2020) 
 9284(final) for “tecartus - brexucabtagene autoleucel”, an orphan medicinal product 
 for human use</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down union procedures for the authorisation and 
 supervision of medicinal products for human use and establishing a european medicines 
 agency
 1,having regard to regulation (ec) no 141/2000 of the european parliament and of the 
 council of 16 december 1999 on orphan medicinal products
 2,having regard to commission regulation (ec) no 1234/2008 of 24 november 2008 
 concerning the examination of variations to the terms of marketing authorisations for 
 medicinal products for human use and veterinary medicinal products
 3, and in particular article 17(2) thereof,
 having regard to the changes to the terms of the decision granting the marketing 
 authorisation requested by kite pharma eu b.v. in accordance with regulation (ec) no 
 1234/2008,
 having regard to the opinions of the european medicines agency, formulated on 21 july 
 2022 by the committee for medicinal products for human use and on 25 july 2022 by the 
 committee for orphan medicinal products,
 whereas:
 (1)
 commission decision c(2020)7318(final), adopted in accordance with regulation 
 (ec) no 141/2000 of the european parliament and of the council of 16 december 
 1999 on orphan medicinal products designated &quot;autologous peripheral blood t cells 
 cd4 and cd 8 selected and cd 3 and cd 28 activated transduced with retroviral 
 vector expressing anti- cd 19 cd 28/ cd 3-zeta chimeric antigen receptor and 
 cultured&quot; as an orphan medicinal product.
 1oj l 136, 30.4.2004, p. 1.2oj l 18, 22.1.2000, p. 1.3oj l 334, 12.12.2008, p. 7.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>(2)the european medicines agency&apos;s opinion is favourable to the variation of the terms 
 of the decision granting the marketing authorisation as submitted by the marketing 
 authorisation holder.
 (3)
 the review of the data submitted by kite pharma eu b.v. on 19 june 2022 has 
 shown that the new therapeutic indication proposed for the medicinal product 
 &quot;tecartus - brexucabtagene autoleucel&quot; brings significant clinical benefit in 
 comparison with existing therapies. therefore, an additional year of marketing 
 protection in accordance with article 14(11) of regulation (ec) no 726/2004 should 
 be granted.
 (4)
 decision c(2020) 9284(final) should therefore be amended accordingly. the union 
 register of medicinal products should also be updated.
 (5)
 for the sake of clarity and transparency, it is appropriate, following the amendment of 
 part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2020) 9284(final) should therefore be replaced.
 has adopted this decision:
 article 1decision c(2020) 9284(final) is amended as follows:1) annex i is replaced by the text set out in annex i to this decision;
 2) annex ii is replaced by the text set out in annex ii to this decision;
 3) annex iii is replaced by the text set out in annex iii to this decision.
 article 2based on the conclusions set out in annex iv to this decision, the additional year of marketing protection is granted in accordance with article 14(11) of regulation (ec) no 
 726/2004.
 article 3this decision is addressed to kite pharma eu b.v., tufsteen 1, 2132 nt hoofddorp, nederland.
 done at brussels, 2.9.2022
 for the commissionsandra gallina
 director-general</p></section></body></xml>